Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | TEC | P42680 | 1/20 | 0.51 |
| ▸ | CD69 | Q07108 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29737150 | 0.91 | BTK (0.71) | BTKEGFRTECCD69 | |
| SCHEMBL18285546 | 0.91 | BTK (0.71) | BTKEGFRTECCD69 | |
| SCHEMBL30970923 | 0.91 | BTK (0.71) | BTKEGFRTECCD69 | |
| SCHEMBL18285696 | 0.91 | BTK (0.71) | BTKEGFRTECCD69 | |
| Oxalic Acid SCHEMBL31683711 | 0.87 | BTK (0.66) | BTKEGFRTECCD69 | |
| SCHEMBL28830810 | 0.86 | BTK (0.62) | BTKEGFRTECCD69 | |
| SCHEMBL18285475 | 0.83 | BTK (0.59) | BTKEGFRTECCD69 | |
| SCHEMBL28076744 | 0.83 | BTK (0.59) | BTKEGFRTECCD69 | |
| SCHEMBL24832588 | 0.78 | BTK (0.47) | BTKEGFRTECCD69 | |
| SCHEMBL24590413 | 0.76 | BTK (0.60) | BTKEGFRTECCD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20180162861-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162861-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-9688676-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688676-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170129890-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170129890-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162861-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | BTK 1/4885EGFR 237/4885TEC 12/4885 |
| US-20170129890-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | BTK 1/4885EGFR 237/4885TEC 12/4885 |
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | BTK 1/4885EGFR 237/4885TEC 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.